MedPacto, Inc. (235980.KQ)
KRW 4585.0
(-1.4%)
KRW 4585.0
(-1.4%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 8.6 Billion KRW | -87.63% |
| 2022 | 69.55 Billion KRW | -8.0% |
| 2021 | 75.6 Billion KRW | 12517.46% |
| 2020 | 599.19 Million KRW | -24.96% |
| 2019 | 798.52 Million KRW | -58.99% |
| 2018 | 1.94 Billion KRW | -55.57% |
| 2017 | 4.38 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 8.4 Billion KRW | -1.63% |
| 2024 Q1 | 8.54 Billion KRW | -0.68% |
| 2023 Q3 | 8.91 Billion KRW | -1.24% |
| 2023 FY | 8.6 Billion KRW | -87.63% |
| 2023 Q4 | 8.6 Billion KRW | -3.51% |
| 2023 Q2 | 9.02 Billion KRW | -1.83% |
| 2023 Q1 | 9.19 Billion KRW | -86.78% |
| 2022 Q4 | 69.55 Billion KRW | 3.61% |
| 2022 Q2 | 62.41 Billion KRW | 5.47% |
| 2022 FY | 69.55 Billion KRW | -8.0% |
| 2022 Q1 | 59.18 Billion KRW | -21.72% |
| 2022 Q3 | 67.12 Billion KRW | 7.55% |
| 2021 Q4 | 75.6 Billion KRW | 2.75% |
| 2021 Q1 | 69.74 Billion KRW | 0.0% |
| 2021 Q2 | 71.64 Billion KRW | 2.72% |
| 2021 FY | 75.6 Billion KRW | 12517.46% |
| 2021 Q3 | 73.58 Billion KRW | 2.7% |
| 2020 Q4 | - KRW | 0.0% |
| 2020 FY | 599.19 Million KRW | -24.96% |
| 2019 FY | 798.52 Million KRW | -58.99% |
| 2018 FY | 1.94 Billion KRW | -55.57% |
| 2017 FY | 4.38 Billion KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| HLB Co., Ltd. | 62.7 Billion KRW | 86.279% |
| iNtRON Biotechnology, Inc. | 402.9 Million KRW | -2035.496% |
| BINEX Co., Ltd. | 53.5 Billion KRW | 83.92% |
| Bioneer Corporation | 44.63 Billion KRW | 80.725% |
| Anterogen.Co.,Ltd. | 9.74 Billion KRW | 11.666% |
| MEDIPOST Co., Ltd. | 52.33 Billion KRW | 83.56% |
| CrystalGenomics, Inc. | 32 Billion USD | 73.115% |
| Helixmith Co., Ltd | 20.22 Billion KRW | 57.464% |
| Chabiotech Co.,Ltd. | 449.63 Billion KRW | 98.086% |
| Medy-Tox Inc. | 82.83 Billion KRW | 89.612% |
| Peptron, Inc. | 9.13 Billion KRW | 5.791% |
| Amicogen, Inc. | 149.59 Billion KRW | 94.248% |
| Genexine, Inc. | 67.42 Billion KRW | 87.239% |
| HLB Therapeutics Co.,Ltd. | 10.02 Billion KRW | 14.151% |
| LegoChem Biosciences, Inc. | 12.64 Billion KRW | 31.951% |
| ALTEOGEN Inc. | 83.76 Billion KRW | 89.729% |
| PharmaResearch Co., Ltd. | 34.3 Billion KRW | 74.92% |
| SillaJen, Inc. | 9.69 Billion KRW | 11.267% |
| JETEMA, Co., Ltd. | 130.49 Billion KRW | 93.407% |
| OliX Pharmaceuticals,Inc | 39.35 Billion KRW | 78.138% |
| Genomictree Inc. | 1.83 Billion KRW | -368.977% |
| D&D Pharmatech | 8.13 Billion KRW | -5.776% |
| EASY BIO,Inc. | 82.27 Billion KRW | 89.543% |
| GI Innovation, Inc. | 3.72 Billion KRW | -131.242% |